Press releases
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
- Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
- Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
- Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
- Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
More ▼
Key statistics
On Tuesday, Sangamo Therapeutics Inc (0R1D:LSE) closed at 0.6513, 124.59% above the 52 week low of 0.29 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.6513 |
Average volume | 18.58k |
---|---|
Shares outstanding | 207.51m |
Free float | 190.69m |
P/E (TTM) | -- |
Market cap | 123.51m USD |
EPS (TTM) | -1.86 USD |
Data delayed at least 20 minutes, as of May 28 2024 17:04 BST.
More ▼